Clinical Trial Details
| Trial ID: | L1921 |
| Source ID: | NCT00832182 |
| Associated Drug: | Insulin Aspart |
| Title: | Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes|Diabetes Mellitus, Type 1 |
| Interventions: | DRUG: insulin aspart|DRUG: insulin NPH |
| Outcome Measures: | Primary: Number of hypoglycemic episodes and adverse events, at 3 and 6 months and at the end of the trial | Secondary: HbA1c, at 3 and 6 months and at the end of the trial|9-point blood glucose profile, at 3 and 6 months and at the end of the trial |
| Sponsor/Collaborators: | Sponsor: Novo Nordisk A/S |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 75 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 1999-12-22 |
| Completion Date: | 2002-11-25 |
| Results First Posted: | |
| Last Update Posted: | 2017-02-23 |
| Locations: | Novo Nordisk Investigational Site, Zagreb, 10 000, Croatia|Novo Nordisk Investigational Site, Praha 10, 10034, Czech Republic|Novo Nordisk Investigational Site, Praha 2, 12821, Czech Republic|Novo Nordisk Investigational Site, Tel Hashomer, 52621, Israel|Novo Nordisk Investigational Site, Moscow, 117036, Russian Federation|Novo Nordisk Investigational Site, Moscow, 119435, Russian Federation|Novo Nordisk Investigational Site, Moscow, 125315, Russian Federation|Novo Nordisk Investigational Site, Moscow, 129110, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, 194354, Russian Federation|Novo Nordisk Investigational Site, Ljubljana, 1000, Slovenia |
| URL: | https://clinicaltrials.gov/show/NCT00832182 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|